Log in to search using one of your social media accounts:

 

Gene Therapy, New Drug Battle a Rare but Deadly Disease in Kids
Source: HealthDay Related MedlinePlus Pages: Genes and Gene Therapy, Spinal Muscular Atrophy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 2, 2017 Category: Consumer Health News Source Type: news

Gene Therapy, New Drug Fight Rare Disease in Kids
Two innovative new therapies for spinal muscular atrophy (SMA) type 1 have proven highly effective in clinical trials, researchers report. (Source: WebMD Health)
Source: WebMD Health - November 1, 2017 Category: Consumer Health News Source Type: news

Gene Therapy, Antisense Show Gains in Spinal Muscular Atrophy Gene Therapy, Antisense Show Gains in Spinal Muscular Atrophy
An antisense oligonucleotide drug and gene therapy each extended survival and led to attainment of motor milestones in some children with spinal muscular atrophy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 1, 2017 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Gene Therapy, New Drug, Spinraza, Battle Rare Spinal Muscular Atrophy in Kids
WEDNESDAY, Nov. 1, 2017 -- Babies born with a previously untreatable degenerative nerve disease now have two fresh sources of hope for their future. Two innovative new therapies for spinal muscular atrophy (SMA) type 1 have proven highly effective... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 1, 2017 Category: General Medicine Source Type: news

New drug enables infants with genetic disorder to live longer, gain motor function
(Nemours) Infants with the most severe form of spinal muscular atrophy (SMA) were more likely to show gains in motor function and were 47 percent more likely to survive without permanent assisted ventilation support when treated with a new medication, according to a study published today in the New England Journal of Medicine. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 1, 2017 Category: Biology Source Type: news

G-CON Manufacturing Announces Completion and Delivery of G-CON...
PODs provide the environments for the entire upstream and downstream process for AveXis’ initial product candidate, AVXS-101, a treatment in development for spinal muscular atrophy (SMA) Type 1, the...(PRWeb October 23, 2017)Read the full story at http://www.prweb.com/releases/2017/10/prweb14830297.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 23, 2017 Category: Pharmaceuticals Source Type: news

Biogen raises 2017 forecast on Spinraza success
(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy. (Source: Reuters: Health)
Source: Reuters: Health - July 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Mother anguish terminally ill newborn baby dying months
Rachael and Jonathan, from Sydney, were over the moon to become first-time parents, until they found out their baby girl, Mackenzie, had Spinal Muscular Atrophy. Rachael spoke to FEMAIL. (Source: the Mail online | Health)
Source: the Mail online | Health - June 22, 2017 Category: Consumer Health News Source Type: news

European Commission approves marketing authorisation for Biogen ’s 5q SMA treatment
The European Commission (EC) has granted marketing authorisation for US-based biotechnology company Biogen ’s Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 1, 2017 Category: Pharmaceuticals Source Type: news

EC Approves First Treatment for SMA: Nusinersen (Spinraza) EC Approves First Treatment for SMA: Nusinersen (Spinraza)
The European Commission has granted marketing authorization for the first treatment for 5q spinal muscular atrophy in the European Union.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

SPINRAZA(R) (nusinersen) Approved in the European Union
First Approved Treatment in EU for SMA Approved to Treat Broad Range of People with SMA Ionis Earns $50 Million Milestone CARLSBAD, Calif., June 1, 2017 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) annou... Biopharmaceuticals, Regulatory Ionis Pharmaceuticals, SPINRAZA, nusinersen, spinal muscular atrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 1, 2017 Category: Pharmaceuticals Source Type: news

Biogen rare infant disease drug Spinraza approved in E.U.
Back in December, Biogen ’s Spinraza became the first drug approved by the FDA to treat spinal muscular atrophy, a top genetic cause of death in infants. Now, the Cambridge-based company has repeated that feat in Europe. Biogen (Nasdaq: BIIB) said Thursday that the European Commission has approved Spinraza, meaning it wi ll become the first drug available in the European Union for SMA patients. The disease is characterized by progressive muscle weakness, and is often fatal. The launch of Spinraza… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 1, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

EU approves Biogen's Spinraza for lead genetic cause of infant death
(Reuters) - Biogen Inc on Thursday said its drug, Spinraza, had secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants. (Source: Reuters: Health)
Source: Reuters: Health - June 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Cytokinetics receives FDA orphan drug status for Ck-2127107 to treat SMA
Biopharmaceutical company Cytokinetics ’ CK-2127107 has received orphan drug designation from the Office of Orphan Products Development of the US Food and Drug Administration (FDA) for the potential treatment of spinal muscular atrophy (SMA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 16, 2017 Category: Pharmaceuticals Source Type: news

Neighborhood Health Plan changes course, will cover Biogen drug for all patients
Citing new clinical data presented last week by Cambridge drugmaker Biogen, the health insurance plan run by Partners HealthCare says it ’s changing its policy and will now pay for a newly approved drug intended to treat all patients with the rare genetic disease, spinal muscular atrophy. In an email to the Boston Business Journal today, Neighborhood Health Plan Chief Medical Officer Dr. Anton Dodek confirmed that the company deci ded to pay for the drug, called Spinraza, for all patients with SMA. “Based… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 2, 2017 Category: American Health Authors: Don Seiffert Source Type: news

New treatment for spinal muscular atrophy discovered
Researchers at Brown University have unlocked the method genetic mutations use to disrupt communication between neurons and muscles in spinal muscular atrophy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 2, 2017 Category: Consumer Health News Source Type: news

New line of attack on spinal muscular atrophy
Scientists have discovered a physiological chain of events in animal models in which motor neurons and their communication with muscle become disrupted by the mutation that causes spinal muscular atrophy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 2, 2017 Category: Science Source Type: news

Study opens new line of attack on spinal muscular atrophy
(Brown University) Scientists have discovered a physiological chain of events in animal models in which motor neurons and their communication with muscle become disrupted by the mutation that causes spinal muscular atrophy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2017 Category: Global & Universal Source Type: news

​Hyde Park boy with rare disease wins appeal, will receive Biogen drug
Doug Hansen of Hyde Park said he has won his appeal of a coverage decision by Neighborhood Health Plan, overturning the health insurance company's refusal to pay for an expensive new drug by Biogen to treat his 11-year-old son, Tyler. Tyler Hansen has spinal muscular atrophy, a very rare disease that that reduces ability to control voluntary muscle movement. The first-ever drug to treat the disease, called Spinraza and marketed by Cambridge-based Biogen (Nasdaq: BIIB), was just approved by the Food… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 26, 2017 Category: American Health Authors: Don Seiffert Source Type: news

SMA Gene Therapy Promising in Early Results
(MedPage Today) -- 12 children with spinal muscular atrophy hit motor milestones in phase I trial of AVXS-101 (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - April 26, 2017 Category: Journals (General) Source Type: news

​New data puts pressure on Partners’ insurance arm to cover Boston boy’s drug
The father of an 11-year-old Boston boy with a rare muscular disease got some new ammunition Monday in his ongoing battle with the health insurance arm of Boston-based Partners HealthCare over its refusal to pay for a pricey new drug. Doug Hansen of Hyde Park says his son, Tyler Hansen, was diagnosed last August with spinal muscular atrophy, a rare genetic disease that reduces ability to control voluntary muscle movement. In December of that year, Cambridge-based Biogen (Nasdaq: BIIB) launched the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 25, 2017 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Biogen profit beats on surprisingly strong Spinraza sales
(Reuters) - Biogen Inc's quarterly profit blew past analysts' estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug, Spinraza. (Source: Reuters: Health)
Source: Reuters: Health - April 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

​Biogen shares jump as launch of new drug beats expectations
Biogen said Tuesday that its recently-approved drug for a rare infant disease had generated far more revenue in the first quarter of 2017 than analysts expected, lifting shares of the Cambridge biotech. Biogen (Nasdaq: BIIB) reported $47 million in first quarter sales of Spinraza, which in December became the first drug approved to treat spinal muscular atrophy, a leading genetic cause of death in infants. That figure easily beat the consensus expectations, which varied but were mostly in the $15 … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 25, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Portsmouth parents desperate for drug to keep son alive
Tyler James Hadley, nine months, from Portsmouth, Hampshire, was born with spinal muscular atrophy type one - the most severe form of the neuromuscular condition. (Source: the Mail online | Health)
Source: the Mail online | Health - April 10, 2017 Category: Consumer Health News Source Type: news

Sleep disorders in spinal muscular atrophy - Pera MC, Romeo DM, Graziano A, Palermo C, Messina S, Baranello G, Coratti G, Massaro M, Sivo S, Arnoldi MT, Mazzone ES, Antonaci L, Lapenta L, Albamonte E, Fanelli L, de Sanctis R, Vita GL, Sframeli M, Pane M, Mercuri E.
OBJECTIVE: To estimate the frequency of sleep disorders in young persons with type 2 and type 3 spinal muscular atrophy (SMA), and to evaluate the relationship between sleep disorders and different variables such as motor impairment, age, use of ventilatio... (Source: SafetyLit)
Source: SafetyLit - February 24, 2017 Category: Global & Universal Tags: Distraction, Fatigue, Chronobiology, Vigilance, Workload Source Type: news

ACOG Recommends Offering All Pregnant Women Additional Carrier Screening (FREE)
By Kelly Young Edited by William E. Chavey, MD, MS All women who are pregnant or are considering becoming pregnant should be offered carrier screening for cystic fibrosis and spinal muscular atrophy and a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 23, 2017 Category: Primary Care Source Type: news

Humana to limit coverage of pricy Biogen drug
Insurance giant Humana has announced it will cover Biogen ’s recently-approved rare disease drug Spinraza, but only for patients with the most severe type of the disorder, called spinal muscular atrophy. Humana (NYSE: HUM) issued its coverage policy on Wednesday for Spinraza, a first-of-its-kind treatment that was approved Dec. 23 and is one of the most expensive rare disease drugs in history. Humana said it would only cover patients with Type 1 SMA, not Types 2 through 4, despite the drug’s… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 9, 2017 Category: Health Management Authors: Max Stendahl Source Type: news

Humana to limit coverage of pricy Biogen drug
Insurance giant Humana has announced it will cover Biogen ’s recently-approved rare disease drug Spinraza, but only for patients with the most severe type of the disorder, called spinal muscular atrophy. Humana (NYSE: HUM) issued its coverage policy on Wednesday for Spinraza, a first-of-its-kind treatment that was approved Dec. 23 and is one of the most expensive rare disease drugs in history. Humana said it would only cover patients with Type 1 SMA, not Types 2 through 4, despite the drug’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 9, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Roche taps Great Lakes, Vivonoetics to passively monitor infants in drug trial
Roche has selected two health technology companies to deploy a wireless wearable system in a clinical trial on a drug for infants with spinal muscular atrophy. (Source: mobihealthnews)
Source: mobihealthnews - February 2, 2017 Category: Information Technology Source Type: news

Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA)
Spinraza (nusinersen) is an anti-sense oligonucleotide indicated for treatment of spinal muscular atrophy (SMA) in paediatric and adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - January 27, 2017 Category: Pharmaceuticals Source Type: news

Four New and Promising Neurology Studies Four New and Promising Neurology Studies
Dr Christoph Diener spotlights potentially practice-changing data in concussion, multiple sclerosis, spinal muscular atrophy, and glioblastoma.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 26, 2017 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news

N.C. babies to get free testing for potentially fatal condition
As early as next year, thousands of North Carolina infants could be tested for symptoms of conditions that could lead to death or disability. The National Center for Advancing Translational Sciences at the National Institutes of Health has awarded funding to a program that will provide free elective genetic testing for spinal muscular atrophy as well as fragile X syndrome in North Carolina infants. Spinal muscular atrophy “is the No. 1 genetic cause of death for infants,” according to nonprofit… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 26, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

Roche taps Vivonoetics, Great Lakes NeuroTech for wearable respiratory assessment device
Roche (PINK:RHHBY) tapped Vivonoetics and Great Lakes NeuroTechnologies, to provide a wearable respiratory testing device to Roche’s Firefish study. The company’s study aims to evaluate drug efficacy compared to respiratory muscle function and breathing patterns in infants treated for spinal muscular atrophy. Devices traditionally used to measure breathing include masks and mouthpieces, which aren’t always practical for monitoring infants. The Firefish study is the 1st large spinal muscular atrophy clinical trial to use a respiratory inductance plethysmography system to non-invasi...
Source: Mass Device - January 25, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: mHealth (Mobile Health) Pediatrics Respiratory Spinal Wall Street Beat Great Lakes NeuroTechnologies Roche Vivonoetics Source Type: news

Spinal Muscular Atrophy: Families' plea over drugs
Families of children with Spinal Muscular Atrophy urge health trust to explain why they are denied access to 'potentially life-changing' drug. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - January 23, 2017 Category: Consumer Health News Source Type: news

New Drug'Transforming' Outlook in Spinal Muscular Atrophy New Drug'Transforming' Outlook in Spinal Muscular Atrophy
Latest results from a phase 3 study of nusinersen show large improvements in motor function and survival, with some infants never predicted to sit up being able to walk. But can Biogen justify the high cost of the drug?Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 17, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Colorado girl is diagnosed with Spinal Muscular Atrophy
At two years old, Lexi Pacini, from Colorado, was diagnosed with Spinal Muscular Atrophy, which weakens the physical muscles. A new drug is helping her learn to walk but her future is unclear. (Source: the Mail online | Health)
Source: the Mail online | Health - January 17, 2017 Category: Consumer Health News Source Type: news

‘Speechless’ Just Schooled Everyone On Disability 'Inspiration Porn'
ABC’s “Speechless,” a sitcom about a family with a son who has a disability, tackled why it’s often offensive to call people with disabilities “inspirational.” And it’s done so, so well. “Inspiration porn” is a term used to describe a common tendency in which able-bodied people condescend to those with disabilities by suggesting they are brave or special just for living. Ray DiMeo, a character in “Speechless” who is the younger brother of a teen with cerebral palsy, explained it perfectly in Wednesday night’s episode: “It’s a portrayal of p...
Source: Healthy Living - The Huffington Post - January 16, 2017 Category: Consumer Health News Source Type: news

Experiments in mice may help boost newly FDA-approved therapy for spinal muscular atrophy
Academic and drug industry investigators say they have identified a new biological target for treating spinal muscular atrophy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 9, 2017 Category: Science Source Type: news

Experiments in mice may help boost newly FDA-approved therapy for spinal muscular atrophy
(Johns Hopkins Medicine) Johns Hopkins researchers along with academic and drug industry investigators say they have identified a new biological target for treating spinal muscular atrophy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 9, 2017 Category: Global & Universal Source Type: news

3 things to know about 2016 drug approvals
In 2016, the U.S. Food and Drug Administration ’s (FDA) Center for Drug Evaluation and Research (CDER)approved 22 new medicines to treat a broad range of illnesses for patients in need. These much-needed new treatments include medicines for multiple sclerosis, chronic lymphocytic leukemia, ovarian and bladder cancer and the very rare spinal muscular atrophy (SMA). (Source: The Catalyst)
Source: The Catalyst - January 6, 2017 Category: Pharmaceuticals Tags: Medicines in Development PhRMA Fact Check FDA Modernization Source Type: news

[In Brief] News at a glance
In science news around the world, China announces a plan to completely phase out its domestic elephant ivory trade by the end of 2017, a Venezuelan lake is the world's top lightning hot spot, the U.S. Food and Drug Administration approves a drug to treat the inherited disease spinal muscular atrophy, the United States creates a new grants program aimed at strengthening the country's manufacturing workforce, and more. Also, famed astronomer Vera Rubin dies. And ecologists ponder the relocation of the descendants of certain escaped exotic pets—considered invasive species in some parts of the world, but critically endan...
Source: ScienceNOW - January 5, 2017 Category: Science Authors: Science Magazine (mailto:soleditor at aaas.org) Tags: SCI COMMUN Source Type: news

Why New Drug Approvals Are At A Six-Year Low In The U.S.
LONDON (Reuters) - Last year turned out to be a disappointing one for new drug approvals with the U.S. Food and Drug Administration clearing just 22 new medicines for sale, the lowest number since 2010 and sharply down on 2015’s tally of 45. Across the Atlantic, the European Medicines Agency recommended 81 new prescription products against a 2015 total of 93. Unlike the FDA, the EMA includes generic drugs in its list. The slowdown suggests the pharmaceuticals industry may be returning to more normal productivity levels after a spike in approvals in 2014 and 2015, when the haul of new drugs reaching the market hit a 1...
Source: Science - The Huffington Post - January 3, 2017 Category: Science Source Type: news

Monthly News Roundup - December 2016
Biogen ’s Spinraza Approved for Spinal Muscular Atrophy The U.S. Food and Drug Administration (FDA) has cleared Biogen's Spinraza (nusinersen), the first drug for spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 31, 2016 Category: Pharmaceuticals Source Type: news

Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval
Spinraza, a “ life-changing ” drug for spinal muscular atrophy, will cost as much as $750,000 for the first year of treatment and $375,000 annually after that. (Source: NYT Health)
Source: NYT Health - December 31, 2016 Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Biogen Idec Inc Spinal Muscular Atrophy Health Insurance and Managed Care Spinraza Source Type: news

​Analyst hikes sales estimates for Biogen’s spinal-disease drug
With earlier-than-expected U.S. approval and a label that includes more patients than previously thought, analysts at Leerink Partners have more than doubled their revenue estimates for the next two years from Biogen ’s new drug for a rare, inherited spinal disease. The Food and Drug Administration late last week approved Spinraza (formerly called nusinersen), the first treatment in the U.S. for spinal muscular atrophy. The drug was developed by Ionis Pharmaceuticals (Nasdaq: IONS), which is based… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 28, 2016 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Biogen, Ionis win FDA approval for first spinal muscular atrophy drug
Biogen (NSDQ:BIIB) said last week that it won FDA approval for its spinal muscular atrophy treatment, Spinraza. The drug is the 1st treatment approved in the U.S. for spinal muscular atrophy, a progressive and often fatal genetic disease that causes muscle weakness in infants and toddlers. The FDA previously granted Biogen’s application fast track designation and priority review, and Spinraza also received orphan drug designation. Get the full story at our sister site, Drug Delivery Business News. The post Biogen, Ionis win FDA approval for first spinal muscular atrophy drug appeared first on MassDevic...
Source: Mass Device - December 28, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Clearance Spinal Biogen Idec Ionis Pharmaceuticals Source Type: news

New FDA-approved drug is offering hope in spinal muscular atrophy
Sofia, now almost 3, was not predicted to live to age 2, let alone stand or walk. All signs were positive when Sofia Wylie was born: normal term delivery, great Apgar scores. “But at her two-month checkup with the pediatrician, she wasn’t lifting her head well, and her reflexes were weak,” says her mother Natalia. “She was like a rag doll.” The pediatrician referred the New Hampshire family to a neurologist. Sofia received genetic testing, and the news wasn’t good: she had spinal muscular atrophy (SMA), a rare paralyzing disease. Even worse, she had the most severe form, SMA Type 1, whic...
Source: Thrive, Children's Hospital Boston - December 28, 2016 Category: Pediatrics Authors: Nancy Fliesler Source Type: news

FDA OK's First Drug for Spinal Muscular Atrophy
Biogen's Spinraza is approved for use across the range of spinal muscular atrophy patients (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 27, 2016 Category: Pharmaceuticals Source Type: news

FDA approves first drug for spinal muscular atrophy
The U.S. Food and Drug Administration has approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. Spinraza is an injection administered into the fluid surrounding the spinal cord. (Source: World Pharma News)
Source: World Pharma News - December 27, 2016 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
CARLSBAD, Calif., Dec. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved SPINRAZATM (nusinersen) under Priority Review for the treatment o... Biopharmaceuticals, FDA Ionis Pharmaceuticals, SPINRAZA, nusinersen, spinal muscular atrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 26, 2016 Category: Pharmaceuticals Source Type: news